医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Gyros Protein Technologies and Abacus ALS Sign Distribution Agreement

2016年12月15日 PM11:00
このエントリーをはてなブックマークに追加


 

UPPSALA, Sweden

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, announced today that it has appointed Abacus ALS as exclusive distributor of its immunoassay products in Australia and New Zealand. Abacus ALS, an ISO 9001: 2008 accredited organization, is one of Australia’s and New Zealand’s largest privately owned companies serving customers in the diagnostic pathology, research and healthcare education industries.

Established in March 2016 through the merger of Gyros AB and Protein Technologies, Inc., Gyros Protein Technologies AB combines Gyros’ microfluidics, systems development and immunoassay expertise with Protein Technologies’ deep knowledge in developing and manufacturing instruments for peptide synthesis. The Company provides customers an unrivaled range of peptide synthesis and bioanalytical tools for biotherapeutics discovery, development and bioprocessing. Abacus ALS will be responsible for sales and technical support for the products that form the Company’s nanoliter-scale immunoassay platform business, including the Gyrolab xP workstation, Gyrolab xPlore, Bioaffy CDs, Gyrolab kits, Rexxip buffers and related reagents and service. These products are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities.

Peter Luk, Vice President Asia-Pacific, Gyros Protein Technologies, said: “Abacus ALS has a proven track record with over fifty years of experience in building successful partnerships and providing excellent service and technical support in the region. This strong market presence and reputation, make them an ideal distribution partner for our immunoassay products. We are pleased to be working with Abacus ALS to build our network of customers in Australia and New Zealand.”

Shayne Christensen, Chief Executive Officer, Abacus ALS, commented: “Our purpose is to connect our Australasian customers with innovative global suppliers, and we are delighted to represent Gyros Protein Technologies in our market.”

ENDS

View source version on businesswire.com: http://www.businesswire.com/news/home/20161215005499/en/

CONTACT

For Gyros Protein Technologies
Lorna Cuddon
Zyme Communications
Tel:
+44(0)7811996942
Email: lorna.cuddon@zymecommunications.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Code Corporation Expands Into Australian Healthcare Market, Signs HPA as New Channel Partner
  • Asahi Kasei and Nara Medical University Confirm 226 nm UVC LED Efficacy Against SARS-CoV-2 and Verify Reduced Effect on Animal Skin Cells
  • HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncology Programs and Validate Its DIS™ Approach in the Clinic
  • Telix Pharmaceuticals and Applied Radiology Launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
  • アジェンディアのマンマプリント検査、NSABP B-42試験で長期内分泌療法の利点を予測する能力を初めて示す